These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 16581145)

  • 1. Utilization of glycoprotein IIb/IIIa inhibitors in non-ST-elevation acute myocardial infarction in a tertiary referral medical center in a developing country.
    Abdallah M; Karrowni W; Dakik HA
    Int J Cardiol; 2007 Jan; 114(2):282-3. PubMed ID: 16581145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and safety of glycoprotein IIb/IIIa inhibitors and clopidogrel alone and in combination in non-ST-segment elevation myocardial infarction (from the National Registry of Myocardial Infarction-4).
    Bromberg-Marin G; Marin-Neto JA; Parsons LS; Canto JG; Rogers WJ;
    Am J Cardiol; 2006 Nov; 98(9):1125-31. PubMed ID: 17056312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes with the use of glycoprotein IIb/IIIa inhibitors in non-ST-segment elevation acute coronary syndromes.
    Dabbous OH; Anderson FA; Gore JM; Eagle KA; Fox KA; Mehta RH; Goldberg RJ; Agnelli G; Steg PG;
    Heart; 2008 Feb; 94(2):159-65. PubMed ID: 17575335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycoprotein IIb-IIIa inhibitors in the emergency department for patients with non-ST-elevation acute coronary syndromes: principles and practices.
    Lefebvre CW; Hoekstra JW; Bonaca M; Giugliano R
    J Emerg Med; 2009 Feb; 36(2):162-70. PubMed ID: 18353601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE).
    Brieger D; Van de Werf F; Avezum A; Montalescot G; Kennelly BM; Granger CB; Goodman SG; Dabbous OH; Agnelli G;
    Am Heart J; 2007 Jun; 153(6):960-9. PubMed ID: 17540196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis.
    O'Donoghue M; Antman EM; Braunwald E; Murphy SA; Steg PG; Finkelstein A; Penny WF; Fridrich V; McCabe CH; Sabatine MS; Wiviott SD
    J Am Coll Cardiol; 2009 Aug; 54(8):678-85. PubMed ID: 19679245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Facilitated angioplasty with combo therapy among patients with ST-segment elevation myocardial infarction: a meta-analysis of randomized trials.
    De Luca G; Marino P
    Am J Emerg Med; 2009 Jul; 27(6):683-90. PubMed ID: 19751625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of different antiplatelet treatment regimens for primary percutaneous coronary intervention on all-cause mortality.
    Witkowski A; Maciejewski P; Wasek W; Malek LA; Niewada M; Kaminski B; Drzewiecki J; Kosmider M; Kubica J; Ruzyllo W; Peruga JZ; Dudek D; Opolski G; Dobrzycki S; Gil RJ;
    Eur Heart J; 2009 Jul; 30(14):1736-43. PubMed ID: 19376786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management and mortality in patients with non-ST-segment elevation vs. ST-segment elevation myocardial infarction. Data from the Malopolska Registry of Acute Coronary Syndromes.
    Dziewierz A; Siudak Z; Dykla D; Rakowski T; Mielecki W; Dubiel JS; Dudek D
    Kardiol Pol; 2009 Feb; 67(2):115-20; discussion 121-2. PubMed ID: 19288373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of glycoprotein IIIa A1/A2 gene polymorphism on one-year outcome in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention.
    Kozieradzka A; Kamiński KA; Pepiński W; Janica J; Korecki J; Skolimowski K; Frankowska E; Kralisz P; Bonda TA; Dobrzycki S; Musiał WJ
    Kardiol Pol; 2006 Dec; 64(12):1350-5; discussion 1356. PubMed ID: 17206538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycoprotein IIb/IIIa inhibitors and the guidelines for treatment of non-ST-elevation myocardial infarction.
    Coplan NL
    J Am Coll Cardiol; 2004 Mar; 43(5):926-7; author reply 927-8. PubMed ID: 14998642
    [No Abstract]   [Full Text] [Related]  

  • 12. Patterns of upstream antiplatelet therapy use before primary percutaneous coronary intervention for acute ST-elevation myocardial infarction (from the CRUSADE National Quality Improvement Initiative).
    Alexander D; Mann N; Ou FS; Peterson ED; Ohman EM; Gibler WB; Roe MT
    Am J Cardiol; 2008 Nov; 102(10):1335-40. PubMed ID: 18993151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors or thienopyridines: results from the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) trial.
    Jolly SS; Faxon DP; Fox KA; Afzal R; Boden WE; Widimsky P; Steg PG; Valentin V; Budaj A; Granger CB; Joyner CD; Chrolavicius S; Yusuf S; Mehta SR
    J Am Coll Cardiol; 2009 Jul; 54(5):468-76. PubMed ID: 19628124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrating GP IIb/IIIa inhibition into treatment strategies for acute ST-elevation myocardial infarction.
    Kandzari DE; Roe MT
    J Invasive Cardiol; 2002 Sep; 14(9):565-74. PubMed ID: 12205361
    [No Abstract]   [Full Text] [Related]  

  • 15. Use of platelet glycoprotein IIb/IIIa inhibitors in saphenous vein graft percutaneous coronary intervention and clinical outcomes.
    Karha J; Gurm HS; Rajagopal V; Fathi R; Bavry AA; Brener SJ; Lincoff AM; Ellis SG; Bhatt DL
    Am J Cardiol; 2006 Oct; 98(7):906-10. PubMed ID: 16996871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between advanced Killip class at presentation and impaired myocardial perfusion among patients with ST-segment elevation myocardial infarction treated with primary angioplasty and adjunctive glycoprotein IIb-IIIa inhibitors.
    De Luca G; Gibson CM; Huber K; Zeymer U; Dudek D; Cutlip D; Bellandi F; Noc M; Emre A; Zorman S; Gabriel HM; Maioli M; Rakowski T; Gyöngyösi M; Van't Hof AW;
    Am Heart J; 2009 Sep; 158(3):416-21. PubMed ID: 19699865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of glycoprotein IIb/IIIa inhibitor use during primary coronary angioplasty: results of propensity analysis using the New York State Percutaneous Coronary Intervention Reporting System.
    Srinivas VS; Skeif B; Negassa A; Bang JY; Shaqra H; Monrad ES
    Am J Cardiol; 2007 Feb; 99(4):482-5. PubMed ID: 17293189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An analysis of the Association of Society of Chest Pain Centers Accreditation to American College of Cardiology/American Heart Association non-ST-segment elevation myocardial infarction guideline adherence.
    Chandra A; Glickman SW; Ou FS; Peacock WF; McCord JK; Cairns CB; Peterson ED; Ohman EM; Gibler WB; Roe MT
    Ann Emerg Med; 2009 Jul; 54(1):17-25. PubMed ID: 19282062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycoprotein IIb/IIIa inhibitors use and outcome after percutaneous coronary intervention for non-ST elevation myocardial infarction.
    Howard JP; Jones DA; Gallagher S; Rathod K; Antoniou S; Wright P; Knight C; Mathur A; Weerackody R; Wragg A
    Biomed Res Int; 2014; 2014():643981. PubMed ID: 24895595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelet GP IIb/IIIa inhibition in unstable angina and non-ST segment elevation MI: application of the ACC/AHA guidelines.
    Young JJ; Choo JK; Kereiakes DJ; ;
    J Invasive Cardiol; 2003 Feb; 15(2):102-7; quiz 108. PubMed ID: 12556626
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.